Tiziana life sciences plans to submit ind for phase 1 trial of intranasal foralumab in alzheimer's disease patients

Company continues to advance foralumab in cns-related inflammatory diseases company continues to advance foralumab in cns-related inflammatory diseases

TLSA Ratings Summary

TLSA Quant Ranking